Abstract
To evaluate tenofovir-related nephropathy, we quantified calculated glomerular filtration rates (GFR) and renal tubular function in 46 tenofovir-treated patients and 25 without tenofovir. We also analysed patients who stopped tenofovir for drug-related nephrotoxicity at our clinic. Tenofovir use combined with non-nucleoside reverse transcriptase inhibitors, but not with protease inhibitors, resulted in a significant increase in calculated GFR. Tenofovir use was associated with significantly lower phosphatemia and a marginally increased fractional excretion of uric acid, but no other signs of tubulopathy.
MeSH terms
-
Adenine / adverse effects
-
Adenine / analogs & derivatives*
-
Adenine / therapeutic use
-
Anti-Retroviral Agents / therapeutic use
-
Case-Control Studies
-
Cross-Sectional Studies
-
Glomerular Filtration Rate
-
HIV Infections / drug therapy*
-
HIV Infections / physiopathology
-
HIV-1*
-
Humans
-
Kidney Diseases / chemically induced*
-
Kidney Diseases / virology
-
Kidney Glomerulus / drug effects
-
Kidney Tubules / drug effects
-
Organophosphonates / adverse effects*
-
Organophosphonates / therapeutic use
-
Reverse Transcriptase Inhibitors / adverse effects*
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Tenofovir
Substances
-
Anti-Retroviral Agents
-
Organophosphonates
-
Reverse Transcriptase Inhibitors
-
Tenofovir
-
Adenine